1 Under-the-Radar Cannabis Stock to Consider Buying

Harvest Health & Recreation Inc (CNX:HARV) possesses strong roots south of the border. Here’s why the cannabis firm is worth considering.

Man considering whether to sell or buy

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The marijuana industry continues its inexorable march forward, particularly in the lucrative U.S. market. In late May, Illinois became the latest state to legalize recreational marijuana by passing bill HB 1438. The piece of legislature was officially signed into law in June.

This development is just the latest in an ongoing transformation within the cannabis industry, which will yield billions of dollars in sales in just a few years.

For Canadian investors looking to profit from the U.S. cannabis market, one option to consider is Harvest Health & Recreation Inc (CNX:HARV). 

One of the largest footprints in the U.S.

One reason Harvest could be an attractive proposition is simply its multi-state presence and the number of stores it owns. As of late June, the vertically integrated cannabis company had the rights to about 210 facilities in the U.S., including 135 retail locations, across about 17 states.

While many other firms can boast a multi-state presence comparable to that of Harvest, none possesses the rights to nearly as many facilities. This factor makes Harvest — in its own words — a cannabis company with one of the largest and deepest footprints in the U.S. 

Harvest achieved its current position in the market largely by way of acquisitions. The latest of these — officially approved by the company’s shareholders during a meeting in June — was the acquisition of Verano Holdings Inc. Verano, one of the largest vertically integrated licensed operators of cannabis facilities, gave Harvest the rights to about 200 facilities across 16 states, including 123 dispensaries.

The all-stock transaction was valued at approximately USD$850,000,000. For a little while, this transaction was the largest acquisition in the U.S. cannabis market. 

Another significant acquisition Harvest made this year was its deal to acquire CannaPharmacy, Inc., a vertically integrated company that operates primarily in four eastern states, namely Maryland, Delaware, New Jersey, and Pennsylvania.

These acquisitions have prepared Harvest to handle the rise in demand for cannabis products better than most of its peers. The firm likely has access to more consumers than almost any of its competitors.

But how has Harvest performed so far?

Financial results

Last year, Harvest generated revenues of about USD $47 million, or about CAD $61 million, representing a 105% increase from 2017. The firm also posted a gross profit margin of 57%, although that was down about 3% from 2017.

The company’s net loss of about USD $67 million was a significant drop from its 2017 net profit of $USD $3,591,000. Harvest’s latest reported financial results, Q2 2019, showed that the company is making headway.

Its revenues of USD $26.6 million represented a 29% sequential increase. Further, Harvest is keeping its foot on the pedal as far as its expansion efforts are concerned.

The firm obtained more than $200 million in funding from a private investment firm and has already opened about half a dozen new retail locations in the third quarter. Finally, Harvest recently acquired the right to distribute its CBD products in more than 10,000 retail stores. 

The bottom line

While Harvest possesses the assets to rack up high sales and revenues for many years to come, it’s doubtful whether the company can earn substantial profits.

In particular, its profit margins have been decreasing, and the addition of all the facilities it acquired in its latest M&A will not make it easy to improve efficiency. In short, while it may be wise to keep an eye on the Vancouver-based company, it might not be the right time to pull the trigger just yet. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Junior Bakiny has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »